The obesity epidemic is closely associated with the rising prevalence and severity of
nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple
steatosis (SS), but also with advanced disease, ie, nonalcoholic steatohepatitis (NASH),
NASH-related cirrhosis and hepatocellular carcinoma. As a consequence, apart from
increasing all-cause mortality, obesity seems to increase liver-specific mortality in NAFLD
patients. Given the lack of approved pharmacological interventions for NAFLD, targeting …

Obesity and NAFLD commonly go together and have a significant global impact. NAFLD is a
broad spectrum of disease ranging from hepatic steatosis to NASH; progression of disease
can move to fibrosis, cirrhosis, and HCC. In addition, complications across organ systems
are life threatening, particularly for CVD. Many times, patients are asymptomatic, so it is
important for other causes of liver disease to be ruled out. Lifestyle modifications are the
mainstay of treatment and include a plan to eat, move, and change behavior. Antiobesity …